Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR
Abstract
Abstract The efficacy, safety and tolerability of bupropion XR and venlafaxine XR was assessed and compared with placebo in adult outpatients with major depressive disorder (MDD). Adults meeting DSM-IV criteria for MDD with a minimum Hamilton Depression Rating Scale (HAMD) 17-Item total score of ≥18 were randomized to eight weeks of double-blind treatment with either bupropion XR (150 mg/day), venlafaxine XR (75 mg/day) or placebo. At the end of the fourth week of treatment, a dosage increase to bupropion XR 300 mg/day or venlafaxine XR 150 mg/day was allowed if, in the opinion of the investigator, response was inadequate. The primary efficacy endpoint was mean change from baseline at week 8 in the Montgomery-Asberg Depression Rating Scale (MADRS) total score last observation carried forward (LOCF). Mean changes from baseline at week 8 (LOCF) in MADRS total score were statistically significant for bupropion XR and venlafaxine XR patients compared to the placebo group: −16.0 for bupropion XR ( P = 0.006 vs placebo), −17.1 for venlafaxine XR ( P < 0.001 vs placebo) and −13.5 for placebo. Secondary outcomes (including CGI-S, HAM-A, MEI, Q-LES-Q-SF, responder and remitter analyses) also improved significantly for both active treatment groups compared with placebo. The most frequently reported adverse events were dry mouth and insomnia for bupropion XR, and nausea, hyperhidrosis, fatigue, and insomnia for venlafaxine XR. In this double-blind, placebo-controlled trial, bupropion XR at doses up to 300 mg/day and venlafaxine XR at doses up to 150 mg/day demonstrated comparable antidepressant efficacy.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The 18-item inpatient version of the MEI has also been used in MDD.
“The 18-item inpatient version has also been used in MDD [83].”
From Patient-reported outcome measures for life engagement in mental health: a systematic review (2022) · cites this paper as [83]
Cites
1 retracted
Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression
Geddes, J. R., Freemantle, N., Mason, J. M., Eccles, M., & Boynton, J. R. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001851 · Cited by 109 · see citing works
RetractedDiagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,841 · see citing works
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Oxford University Press eBooks · doi:10.1037/10518-009 · Cited by 19,767 · see citing works
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988 · see citing works
Depression in Late Life: Review and Commentary
Blazer, D. G. (2003) · The Journals of Gerontology Series A · doi:10.1093/gerona/58.3.m249 · Cited by 2,363 · see citing works
The ESEMeD/MHEDEA 2000 Investigators, Alonso, J., Angermeyer, M. C., Bernert, S., Bruffaerts, R., Brugha, T. S., Bryson, H., de Girolamo, G., de Graaf, R., Demyttenaere, K., et al. (2004) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0047.2004.00327.x · Cited by 1,825 · see citing works
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033 · see citing works
Distributed Disturbances in Brain Structure and Function in Schizophrenia
Lewis, D. A. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.1 · Cited by 971 · see citing works
Stahl, S. M., Pradko, J., Haight, B. R., Modell, J. G., Rockett, C. B., & Learned-Coughlin, S. (2004) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v06n0403 · Cited by 495 · see citing works
Self-citationStahl, S. M., Grady, M. M., Moret, C., & Briley, M. (2005) · CNS Spectrums · doi:10.1017/s1092852900019726 · Cited by 462 · see citing works
The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity.
Clayton, A. H., McGarvey, E. L., & Clavet, G. J. (1997) · PubMed · Cited by 352 · see citing works
Thase, M. E., Haight, B. R., Richard, N., Rockett, C. B., Mitton, M., Modell, J. G., VanMeter, S., Harriett, A. E., & Wang, Y. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0803 · Cited by 304 · see citing works
Self-citation15 Years of Clinical Experience With Bupropion HCl
D, M. F. M., Rush, A. J., Thase, M. E., Clayton, A. H., Stahl, S. M., Pradko, J. F., & Johnston, J. A. (2005) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v07n0305 · Cited by 258 · see citing works
Croft, H. A., Settle, E. C., Houser, T. L., Batey, S. R., Donahue, R. M. J., & Ascher, J. A. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)88317-4 · Cited by 243 · see citing works
Kennedy, S. H., Andersen, H. F., & Lam, R. W. M. (2006) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0615 · Cited by 216 · see citing works
Coleman, C. C., King, B., Bolden-Watson, C., Book, M. J., Segraves, R., Richard, N., Ascher, J., Batey, S. R., Jamerson, B., & Metz, A. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80090-4 · Cited by 171 · see citing works
Bupropion Sustained Release Versus Paroxetine for the Treatment of Depression in the Elderly
Weihs, K. L., Settle, E. C., Batey, S. R., Houser, T. L., Donahue, R. M. J., & Ascher, J. A. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0309 · Cited by 150 · see citing works
Coleman, C. C., Cunningham, L. A., Foster, V. J., Batey, S. R., Donahue, R. M. J., Houser, T. L., & Ascher, J. A. (1999) · Annals of Clinical Psychiatry · doi:10.1023/a:1022309428886 · Cited by 131 · see citing works
Seasonal Affective Disorder and Its Prevention by Anticipatory Treatment with Bupropion XL
Modell, J. G., Rosenthal, N. E., Harriett, A. E., Krishen, A., Asgharian, A., Foster, V. J., Metz, A. L., Rockett, C. B., & Wightman, D. S. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.021 · Cited by 124 · see citing works
Self-citationThe Safety and Tolerability of Venlafaxine Hydrochloride: Analysis of the Clinical Trials Database
Rudolph, R. L., & Derivan, A. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199606002-00011 · Cited by 122 · see citing works
Coleman, C., Cunningham, L., Foster, V., et al. (1999) · Annals of Clinical Psychiatry · doi:10.3109/10401239909147072 · Cited by 105 · see citing works
Little, J. T., Ketter, T. A., Kimbrell, T. A., Dunn, R. T., Benson, B. E., Willis, M. W., Luckenbaugh, D. A., & Post, R. M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.10.033 · Cited by 96 · see citing works
Kobak, K. A., Greist, J. H., Jefferson, J. W., Mundt, J. C., & Katzelnick, D. J. (1999) · PubMed · Cited by 95 · see citing works
A Double-blind Comparison Between Bupropion XL and Venlafaxine XR
Thase, M. E., Clayton, A. H., Haight, B. R., Thompson, A. H., Modell, J. G., & Johnston, J. A. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000239790.83707.ab · Cited by 90 · see citing works
Self-citationSelecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects.
Stahl, S. M. (1998) · PubMed · Cited by 84 · see citing works
A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients.
Lineberry, C. G., Ja, J., Rn, R., SAMARA, B., Feighner, J. P., Harto-Truax, N., Granacher, R. P., Weisler, R. H., Js, C., & Wf, B. (1990) · PubMed · Cited by 75 · see citing works
Weihs, K. L., Houser, T. L., Batey, S. R., Ascher, J. A., Bolden-Watson, C., Donahue, R. M. J., & Metz, A. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01317-8 · Cited by 65 · see citing works
Chrzanowski, W., Rousseau, R., Hewett, K., Gee, M., Wightman, D. S., Richard, N. E., Modell, J. G., & Goodale, E. P. (2006) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(06)70340-6 · Cited by 4 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Assessing anhedonia in depression: potentials and pitfalls
Rizvi, S. J., Pizzagalli, D. A., Sproule, B. A., & Kennedy, S. H. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.03.004 · Cited by 571 · see citing works
Wolff, Ä., Joshi, R. K., Ekström, J., Aframian, D. J., Pedersen, A. M. L., Proctor, G., Narayana, N., Villa, A., Sia, Y. W., Aliko, A., et al. (2016) · Drugs in R&D · doi:10.1007/s40268-016-0153-9 · Cited by 379 · see citing works
Spielmans, G. I., Berman, M. I., Linardatos, E., Rosenlicht, N. Z., Perry, A., & Tsai, A. C. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001403 · Cited by 275 · see citing works
Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant
Patel, K., Allen, S., Haque, M. N., Angelescu, I., Baumeister, D., & Tracy, D. K. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316629071 · Cited by 198 · see citing works
Restoring function in major depressive disorder: A systematic review
Sheehan, D. V., Nakagome, K., Asami, Y., Pappadopulos, E. A., & Boucher, M. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.02.029 · Cited by 182 · see citing works
Ghanean, H., Ceniti, A. K., & Kennedy, S. H. (2018) · CNS Drugs · doi:10.1007/s40263-018-0490-z · Cited by 108 · see citing works
Weisler, R. H., Joyce, J. M., McGill, L., Lazarus, A. L., Szamosi, J., Eriksson, H., & Moonstone Study Group (2009) · CNS Spectrums · doi:10.1017/s1092852900020307 · Cited by 109 · see citing works
Hewett, K., Gee, M., Krishen, A., Wunderlich, H.-P., Clus, A. L., Evoniuk, G. E., & Modell, J. G. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109106953 · Cited by 65 · see citing works
Self-citationUsing the Analytic Hierarchy Process to Elicit Patient Preferences
Hummel, M. J. M., Volz, F., van Manen, J. G., Danner, M., Dintsios, C., IJzerman, M. J., & Gerber, A. (2012) · Patient · doi:10.1007/bf03262495 · Cited by 63 · see citing works
The Impact of Psychotherapy, Pharmacotherapy, and Their Combination on Quality of Life in Depression
IsHak, W. W., Ha, K., Kapitanski, N., Bagot, K. S., Fathy, H., Swanson, B. N., Vilhauer, J. S., Balayan, K., Bolotaulo, N. I., & Rapaport, M. H. (2011) · Harvard Review of Psychiatry · doi:10.3109/10673229.2011.630828 · Cited by 57 · see citing works
Patient-reported outcome measures for life engagement in mental health: a systematic review
McIntyre, R. S., Ismail, Z., Watling, C. P., Weiss, C., Meehan, S. R., Musingarimi, P., & Thase, M. E. (2022) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-022-00468-5 · Cited by 48 · see citing works
Meta-analysis: Risk of dry mouth with second generation antidepressants
Cappetta, K., Beyer, C., Johnson, J. A., & Bloch, M. H. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.12.012 · Cited by 49 · see citing works
The Efficacy and Tolerability of Bupropion in the Treatment of Major Depressive Disorder
Moreira, R. (2011) · Clinical Drug Investigation · doi:10.2165/1159616-s0-000000000-00000 · Cited by 46 · see citing works
Less Is More in Antidepressant Clinical Trials
Rutherford, B. R., Cooper, T. M., Persaud, A., Brown, P. J., Sneed, J. R., & Roose, S. P. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r08267 · Cited by 40 · see citing works
Spielmans, G. I., & Gerwig, K. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000356191 · Cited by 30 · see citing works
Kinesin-1 promotes chondrocyte maintenance during skeletal morphogenesis
Santos‐Ledo, A., Macia, M. G., Campbell, P. D., Grońska-Pęski, M., & Marlow, F. L. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1006918 · Cited by 29 · see citing works
Trémeau, F., Goldman, J., Antonius, D., & Javitt, D. C. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.05.031 · Cited by 28 · see citing works
McCarty, D. E. (2010) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27829 · Cited by 28 · see citing works
Meta-analysis: Risk of hyperhidrosis with second-generation antidepressants
Beyer, C., Cappetta, K., Johnson, J. A., & Bloch, M. H. (2017) · Depression and Anxiety · doi:10.1002/da.22680 · Cited by 23 · see citing works
Meta-analysis: Second generation antidepressants and headache
Telang, S., Walton, C., Olten, B., & Bloch, M. H. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.04.047 · Cited by 23 · see citing works
Spielmans, G. I., Berman, M. I., Linardatos, E., Rosenlicht, N. Z., Perry, A., & Tsai, A. C. (2016) · Focus · doi:10.1176/appi.focus.140202 · Cited by 20 · see citing works
Wiesinger, T., Kremer, S., Bschor, T., & Baethge, C. (2023) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13541 · Cited by 23 · see citing works
Kamp, C. B., Petersen, J. J., Faltermeier, P., Juul, S., Siddiqui, F., Moncrieff, J., Horowitz, M. A., Hengartner, M. P., Kirsch, I., Gluud, C. N., et al. (2024) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796024000520 · Cited by 22 · see citing works
Tafseer, S., Gupta, R., Ahmad, R. S., Jain, S., Bhatia, M. S., & Gupta, L. K. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.173073 · Cited by 19 · see citing works
Maneeton, B., Maneeton, N., Eurviriyanukul, & Srisurapanont, M. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s46849 · Cited by 19 · see citing works
Drug Class Review: Second-Generation Antidepressants
Gartlehner, G., Hansen, R. A., Reichenpfader, U., Kaminski, A., Kien, C., Strobelberger, M., Noord, M. V., Thieda, P., Thaler, K. J., & Gaynes, B. N. (2011) · Cited by 17 · see citing works
Mundi, J. P., Betancourt, J., Ezziddin, O., Tremayne, B., Majic, T., & Mosenifar, Z. (2012) · Journal of Intensive Care Medicine · doi:10.1177/0885066611429661 · Cited by 17 · see citing works
Thase, M. E., Gommoll, C., Chen, C., Kramer, K. L., & Sambunaris, A. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000138 · Cited by 15 · see citing works
Evans, V. C., Alamian, G., McLeod, J., Woo, C., Yatham, L. N., & Lam, R. W. M. (2016) · CNS Drugs · doi:10.1007/s40263-016-0334-7 · Cited by 15 · see citing works
Peters, E. M., Balbuena, L., & Lodhi, R. J. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.08.066 · Cited by 13 · see citing works
Locklear, J. C., Svedsäter, H., Datto, C. J., & Endicott, J. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.01.021 · Cited by 14 · see citing works
Getting the balance right: Established and emerging therapies for major depressive disorders
Vezmar (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s10485 · Cited by 12 · see citing works
Leidenfrost, C. M., Schoelerman, R. M., Maher, M. J., & Antonius, D. (2017) · International Journal of Law and Psychiatry · doi:10.1016/j.ijlp.2017.06.004 · Cited by 12 · see citing works
Practical pathway for the management of depression in the workplace: a Canadian perspective
Chokka, P. R., Bender, A., Brennan, S., Ahmed, G., Corbière, M., Dozois, D. J. A., Habert, J., Harrison, J., Katzman, M. A., McIntyre, R. S., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1207653 · Cited by 12 · see citing works
Sarfati, D., Evans, V. C., Tam, E. M., Woo, C., Iverson, G. L., Yatham, L. N., & Lam, R. W. M. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000192 · Cited by 10 · see citing works
Epileptic seizures, coma and EEG burst‐suppression from suicidal bupropion intoxication
Noda, A. H., Schu, U., Maier, T., Knake, S., & Rosenow, F. (2017) · Epileptic Disorders · doi:10.1684/epd.2017.0896 · Cited by 10 · see citing works
Shen, Y., Zhao, Q., Yu, Y., Tan, Y., Zhang, H., Xu, X., Wang, Z., Li, Y., Hu, J., Zhong, J., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.07.023 · Cited by 9 · see citing works
Ostinelli, E. G., Salanti, G., Macleod, M. R., Chiocchia, V., Smith, K., Stringaris, A. K., Downs, J. L., Robinson, E. S. J., Malhi, G. S., Dwyer, D. M., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105967 · Cited by 8 · see citing works
Kremer, S., Wiesinger, T., Bschor, T., & Baethge, C. (2023) · Psychotherapy and Psychosomatics · doi:10.1159/000533494 · Cited by 8 · see citing works
Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression
Gartlehner, G., Hansen, R. A., Morgan, L. C., Thaler, K. J., Lux, L. J., Noord, M. V., Mager, U., Gaynes, B. N., Thieda, P., Strobelberger, M., et al. (2011) · Cited by 8 · see citing works
Antipsychotic Monotherapy for Major Depressive Disorder: A Systematic Review and Meta-Analysis
Nishi, A., Sawada, K., Uchida, H., Mimura, M., & Takeuchi, H. (2022) · Pharmacopsychiatry · doi:10.1055/a-1934-9856 · Cited by 6 · see citing works
Cheung, C. P., Thiyagarajah, M., Abraha, H. Y., Liu, C. S., Lanctôt, K., Kiss, A., Saleem, M., Juda, A., Levitt, A., Schaffer, A., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.11.004 · Cited by 5 · see citing works
Zhang, F., Li, Y., Hu, J., Zhong, J., & Li, H. (2018) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-018-0537-z · Cited by 6 · see citing works
Depression and Anxiety Disorders
Karamustafalıoğlu, O., & Yumrukçal, H. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg003.pub2 · Cited by 7 · see citing works
Gründer, G. (2026) · Pharmacopsychiatry · doi:10.1055/s-00000054 · Cited by 6 · see citing works
Meta-analysis of placebo group dropout in adult antidepressant trials
Li, F., Nasir, M., Olten, B., & Bloch, M. H. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109777 · Cited by 5 · see citing works
Anhedonia in depressive disorders
Siwek, M. (2017) · Psychiatria i Psychologia Kliniczna · doi:10.15557/pipk.2017.0026 · Cited by 5 · see citing works
Novitsky, M. A., Sousa, A. D., Asadullin, A. R., Gavrilyuk, O. A., Petrov, A. V., & Nasyrova, R. F. (2021) · Personalized Psychiatry and Neurology · doi:10.52667/2712-9179-2021-1-2-21-45 · Cited by 3 · see citing works
Taurines, R., Gerlach, M., & Warnke, A. (2016) · Springer eBooks · doi:10.1007/978-3-662-48624-5_5 · Cited by 2 · see citing works
Taurines, R., Warnke, A., Greenhill, L. L., & Gerlach, M. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1501-5_4 · Cited by 2 · see citing works
Depression and Anxiety Disorders
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg003 · Cited by 1 · see citing works
The Role of Bupropion in the Management of Major Depressive Disorder
Ha, K., Tawadros, Y., & IsHak, W. W. (2011) · Clinical Medicine Reviews in Therapeutics · doi:10.4137/cmrt.s20
Noradrenaline dopamine-reuptake inhibitors
Silverstone, P. H. (2012) · doi:10.2217/ebo.11.262
Current awareness in human psychopharmacology
(2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1059
Taurines, R., & Gerlach, M. (2023) · Springer eBooks · doi:10.1007/978-3-662-65267-1_5
- Authors
- Hewett, K., Chrzanowski, W., Schmitz, M., Savela, A., Milanova, V, Gee, M., Krishen, A., Millen, L., Leary, M., & Modell, J.
- Affiliations
- GlaxoSmithKline (United Kingdom) (GB)
- Psychiatric Clinic, Academy of Medicine, Choroszcz, Poland
- Department of Psychiatry, Psychosomatic Institute, Vienna, Austria
- Department of Psychiatry, Klaara-Keskus, Helskinki, Finland
- Alexandrovska Hospital (BG)
- GlaxoSmithKline, Research Triangle Park, NC, USA
- Corresponding author
- Hewett, K
- ORCID
- Milanova, V
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2008-07-17
- Volume
- 23
- Issue
- 5
- Pages
- 531-538
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2029297015
- Cited by
- 57
- References
- 27
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 6 · 2022: 3 · 2021: 2 · 2020: 2 · 2019: 2 · 2018: 3 · 2017: 8 · 2016: 7 · 2014: 2 · 2013: 5 · 2012: 3
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- bupropion, venlafaxine, major depressive disorder, antidepressant efficacy, drug tolerability, adverse events, xerostomia, insomnia, dose escalation, placebo comparison
- MeSH terms
- Venlafaxine Hydrochloride, Adult, Cyclohexanols, Delayed-Action Preparations, Major Depressive Disorder, Double-Blind Method, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Psychometrics, Bupropion, Antidepressive Agents, Second-Generation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
